A Phase II Study Of OSI-774 [erlotinib] In Metastatic Colorectal Cancer

Trial Profile

A Phase II Study Of OSI-774 [erlotinib] In Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2013

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 23 Jan 2013 Primary endpoint amended as reported by ClinicalTrials.gov.
    • 23 Jan 2013 Actual end date added 1 May 2007 as reported by ClinicalTrials.gov.
    • 08 May 2007 Status changed from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top